Berdagang Vir Biotechnology VIR

VirBiotechnology carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tunjukkan lebih lagi
Frances Wang 2025 Jul 27, 16:00

Trending Stocks Today: PLTR Stock , MCVT Stock, SMCI Stock, NVDA Stock

Stocks
Interest rate cut percentage
Tommy Yap 2025 Jul 26, 21:00

Week Ahead: Interest Rate Decisions from Fed, BoC, and BoJ in Focus

Forex Indices
Liam James 2025 Jul 25, 10:20

ECB Rate Cut Expectations Revised Amid Economic Resilience

Ava Grace 2025 Jul 25, 09:20

Hedge Funds Advise Buying Protection Against Potential Stock Market Downturn

Liam James 2025 Jul 25, 08:20

Federal Funds Rate vs. SOFR: Liquidity Measurement Debate in US Financial System

Ava Grace 2025 Jul 25, 07:20

Musk Praises Tesla Autopilot Performance in China Test, Sparking Debate

Emma Rose 2025 Jul 25, 06:20

Europe Offers Iran Extension on Sanctions Deadline Amid Nuclear Program Concerns

Noah Lee 2025 Jul 25, 05:20

BOJ Rate Hike Outlook: US Trade Deal Creates Space, But Challenges Remain

Maklumat

Sebaran nilai

0.05

Spread (%)

0.9208 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Selasa

13:31 - 19:59

Isnin

13:31-19:59

Rabu

13:31-19:59

Khamis

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

781044736

Saham Tertunggak

138238000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-4.23

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tunjukkan lebih lagi
Trustpilot